WO1991004051A1 - Peptides including ctl epitopes of hiv proteins and use thereof - Google Patents
Peptides including ctl epitopes of hiv proteins and use thereof Download PDFInfo
- Publication number
- WO1991004051A1 WO1991004051A1 PCT/US1990/005343 US9005343W WO9104051A1 WO 1991004051 A1 WO1991004051 A1 WO 1991004051A1 US 9005343 W US9005343 W US 9005343W WO 9104051 A1 WO9104051 A1 WO 9104051A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide fragment
- animal
- ctl
- cells
- hiv
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 21
- 102000004169 proteins and genes Human genes 0.000 title claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 title description 38
- 102000004196 processed proteins & peptides Human genes 0.000 title description 18
- 102000007079 Peptide Fragments Human genes 0.000 claims abstract description 73
- 108010033276 Peptide Fragments Proteins 0.000 claims abstract description 73
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 42
- 241001465754 Metazoa Species 0.000 claims abstract description 32
- 102100034353 Integrase Human genes 0.000 claims abstract description 18
- 108010078428 env Gene Products Proteins 0.000 claims abstract description 18
- 101710192141 Protein Nef Proteins 0.000 claims abstract description 17
- 101710177291 Gag polyprotein Proteins 0.000 claims abstract description 14
- 101710125418 Major capsid protein Proteins 0.000 claims abstract description 14
- 208000015181 infectious disease Diseases 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 33
- 230000004044 response Effects 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 15
- 238000003556 assay Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 11
- 230000003190 augmentative effect Effects 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 8
- 230000009089 cytolysis Effects 0.000 claims description 7
- -1 or E)(T Inorganic materials 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000024932 T cell mediated immunity Effects 0.000 abstract description 3
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 abstract description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 76
- 235000018102 proteins Nutrition 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 7
- 241000700618 Vaccinia virus Species 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical class C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108700004028 nef Genes Proteins 0.000 description 1
- 101150023385 nef gene Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Peptide fragments of HIV proteins such as NEF protein, GAG protein, and ENV protein, which include a CTL epitope. Such peptide fragments containing CTL epitopes may be used to induce or augment cellular immune responses against HIV virus to treat or prevent infection of the animal with HIV virus.
Description
PEPTIDES INCLUDING CTL EPITOPES OF HIV PROTEINS AND USE THEREOF
This invention relates to peptides which include a CTL epitope. The peptides or derivatives thereof may be used to induce and/or augment a CTL response. More particularly, this invention relates to HIV (Human Immunodeficiency Virus) proteins and peptide fragments which include CTL epitopes, and which may be used to induce a CTL response to HIV virus.
Cell-mediated immunity (or CMI) of virus infections is thought to be a major line of host defense against viral infections. CMI may be significant in the development of an effective vaccine against human immunodeficiency virus (HIV), or AIDS virus because HIV vaccines and/or therapies based on the generation of passive transfer of HIV-specific antibody in the absence of cell-mediated immunity have not yielded consistent protection in primates challenged with the HIV virus. Thus, interest has turned to the induction of cell-mediated immune responses to HIV and to the identification of specific epitopes of HIV proteins that stimulate a cytotoxic T lymphocyte, (or CTL) response.
In accordance with an aspect of the present invention, there is provdied a peptide fragment which includes an epitope which is recognized by cytotoxic T lymphocytes (CTL) induced by an HIV protein or CTL epitope thereof. The HIV protein is preferably an HIV-1 protein.
In a preferred aspect , the peptide fragment is recognized by CTL induced by the NEF, GAG, or ENV protein, or a CTL epitope thereof.
The term "peptide fragment" as used herein means a peptide having a number of amino acid residues less than the number of amino acid residues present in the native protein which includes the CTL epitope.
A peptide fragment which includes an epitope which is recognized by CTL induced by an HIV protein is sometimes herein referred to as a peptide fragment containing a CTL epitope.
The peptide fragment may be a fragment of the native protein or an analogue or derivative thereof, provided that such peptide fragment is recognized by CTL induced by the native protein or CTL epitope of such native protein.
The peptide fragment may be comprised of only the amino acid residues which form the CTL epitope, or it may include additional amino acid residues; however, as hereinabove noted, the fragment contains less amino acid residues than the native protein.
In accordance with one embodiment, there is provided a peptide fragment which includes an epitope which is recognized by CTL induced by the NEF protein of HIV-1 (hereinafter sometimes referred to as NEF protein) . The peptide fragment which includes a CTL epitope which is recognized by CTL induced by NEF protein may be a fragment of the NEF protein containing such a CTL epitope or an analogue or
derivative thereof. The CTL epitope of the NEF protein is contained in amino acid residues 73 to 97 of NEF protein according to the Los Alamos, National Laboratory HIV sequence data base as follows (single letter amino acid code)
QVPLRPMT(Y or F, preferably Y)KAAVDLSHFLKEKGGL, and more particularly, such CTL is comprised of residues 73 to 82 (Los Alamos sequence), which have the following structure as defined by the single letter amino acid code:
QVPLRPMT(Y or F, preferably Y)K. In accordance with another embodiment , there is provided a peptide fragment which includes an epitope which is recognized by CTL induced by the GAG protein of HIV-1 or CTL epitope thereof (sometimes hereinafter referred to as GAG protein) . The peptide fragment which includes a CTL epitope which is recognized by CTL induced by GAG protein may be a fragment of the GAG protein containing such a CTL epitope or an analogue or derivative thereof. The CTL epitope of the GAG protein is contained in amino acid residues 179 to 193 of the GAG protein, which has the following structure as defined by the single letter amino acid code:
ATPQDLN(T or M, preferably T)MLN(T or I, preferably T)VGG.
In accordance with yet another embodiment , there is provided a peptide fragment which includes an epitope which is recognized by CTL induced by the ENV protein of HIV-1 or CTL epitope thereof (sometimes hereinafter referred to as ENV protein) . The peptide fragment which includes a CTL epitope which is recognized by CTL induced by ENV protein may be a fragment of the ENV protein containing such a CTL epitope or an analogue or derivative thereof. The
CTL epitope of the ENV protein is contained in amino acid residues 566 to 590 of the ENV protein, which has the following structure as defined by the single letter amino acid code:
LQLTVWGIKQLLAR(I or V, preferably I)LAVERYL(K or R, preferably )DQ.
In accordance with a further embodiment, there is provided a peptide fragment which includes another epitope which is recognized by CTL induced by the ENV protein of HIV-1 or a CTL epitope thereof. This CTL epitope of the ENV protein is contained in amino acid residues 54 to 80 of the ENV protein, which has the following structure as defined by the letter amino acide code:
CAS (D or E, preferably D)A(K or R, preferably K)(A or S, preferably A)Y(D,S,K, or E, preferably D)(T,K, or P, preferably T)E(V,A,S, or K, preferably V)HN(V or I, preferably V)WA(T or K, preferably T)(H or Q, preferably H)ACVP(T or S, preferably T)(D or N, preferably D)P(N or S, preferably N).
The peptides hereinabove described may be produced by known techniques and obtained in substantially pure form. For example, the peptides may be synthesized on an automatic synthesizer. Journal of the American Chemical Society, Vol. 85, pages 2149-54 (1963). It is also possible to produce such peptides by genetic engineering techniques. The peptide may also be produced by chemical or enzymatic buildup from smaller peptide fragments , or by cleavage of larger peptides or proteins or by solution phase peptide synthesis.
In accordance with another aspect of the present invention, a peptide fragment which includes an epitope, which is recognized by CTL induced by an HIV protein, may be employed in an assay for determining
HIV infection. More particularly, the assay comprises contacting cells coated with a peptide fragment including a CTL epitope, which is recognized by CTL induced by a HIV protein, with lymphocytes from the animal, and determining lysis of the cells to indicate infection of the animal with HIV. The cells coated with peptide are either autologous cells or an in vitro cell line compatible with the HLA type (MHC allele(s)) of the animal being tested. The peptide fragment containing a CTL epitope may be a peptide fragment of the NEF protein, or a peptide fragment of the GAG protein, or a peptide fragment of the ENV protein or analogs or derivatives thereof as hereinabove described, or mixtures thereof. In general, such an assay is effective for testing an individual of a particular HLA type for CMI responses to said peptide fragments .
In one embodiment, B-cells from the animal are coated with a peptide fragment having a CTL epitope of an HIV protein as hereinabove described. The B-cells may include a detectable label or marker, such as a radioactive chromium marker. The B-cells are then contacted with peripheral blood lymphocytes (or PBL) from the animal. If the peripheral blood lymphocytes contain CTL induced by an HIV protein containing the CTL epitope of the peptide fragment , the CTL will recognize the CTL epitope of the peptide fragment coating the B-cells, and will lyse the B-cells. Lysis of the B-cells will be indicated by release of the detectable marker into the assay medium. If there is lysis of the B-cells as indicated by release of the detectable marker into the medium, then the peripheral blood lymphocytes contain CTL induced by an HIV protein and the animal is infected with HIV.
In accordance with yet another aspect of the present invention, there is provided a process for augmenting a CTL response which comprises contacting peripheral blood lymphocytes from an animal infected with HIV with a peptide fragment(s) including a CTL epitope as hereinabove described. The peptide fragment preferably contains a CTL epitope of the NEF protein, or a CTL epitope of the GAG protein, or a CTL epitope of the ENV protein. The CTL response may be induced in vitro. The CTL response may be augmented in vitro by incubating peripheral blood mononuclear cells (PBMC's) from seropositive individuals with a peptide of the type hereinabove described.
The peripheral blood lymphocytes having augmented CTL may then be used to treat the animal. For example, PBL augmented in CTL may be administered intravenously as an appropriate physiological suspension (for example in PBS) containing from 10 to 1010 cells.
In accordance with another aspect, CTL may be induced in vivo by administering to an animal infected with HIV a peptide fragment having a CTL epitope of the type hereinabove described. More particularly, CTL will be induced in vivo by immunization with constructs that contain CTL sites against HIV that have been described above (E.g. Nef7). These vaccines can be formulated using standard techniques with carriers and/or adjuvants (for example, alum, bacterial cell wall components, vegetable oil formulations or derivatives thereof, etc.) to induce CTL responses. In addition, a peptide or peptide derivative having a CTL epitope can be synthesized and/or chemically modified to contain exogenous amino acids and/or fatty acid or
hydrophobic moieties necessary for induction and/or augmentation of a CTL response. An example of a method of modifying a peptide or peptide derivative having a CTL epitope is described in Deres , et al, Nature, Vol. 342, November 30, 1989, pgs . 561-564. The dosage and administration protocol can be optimized in accordance with standard vaccination practices. A useful dosage for an average adult can be in the range of 1.0 to 1500 micrograms.
The invention will now be described with respect to the following examples; however, the scope of the invention is not to be limited thereby.
EXAMPLE I (a) Recombinant vaccinia virus construction. The nef coding sequence was obtained from Dr. Venkatesan, Laboratory of Medical Microbiology, NIAID, NIH, as a cDNA clone. The cDNA was derived from the HIV isolate, NL432 (Adachl et a. (1986) J. Virol. 59, 284). Using standard recombinant DNA technique, the nef gene was excised and placed into a vaccinia virus integration vector. The integration vector contains a vaccinia virus promoter termed P 7.5. Promoter P 7.5 allows expression of foreign genes at early and late times after infection. The nef coding sequence was placed downstream of p 7.5. The P 7.5 nef casette was inserted into the thymidine kinase (TK) locus of vaccinia virus by standard procedures resulting in insertional inactivation of TK. A TK-recombinant vaccinia virus, designated vTFnef, was isolated and purified. Expression studies were performed with vTFnef to confirm proper expression of Nef. Cell monolayers were infected with vTFnef in the presence of radiolabeled amino acids or myristic acid. Cell lysates were
immunoprecipitated with Nef anti-serum. A specific 27 kd protein was precipitated. The 27 kd protein corresponds to the predicted molecular size as well as previously reported values for Nef (J.S. Allan et al., Science (1985) 230, 810; G. Franchini et al. , Virology (1986) 155, 593). Nef is also myristoylated demonstrating authentic expression of the nef coding sequence.
(b) Identification of individuals with Nef-specific CTL responses. Recombinant virus, vTFnef, was used to screen circulating T lymphocytes for CTL activity directed to Nef from a group of 12 healthy, HIV-1 seropositive HIV-1 patients. Fresh peripheral blood mononuclear cells (PBMC) were obtained from these patients and tested for cytolytic activity against autologous cells infected with vTFnef. Unfractionated PBMC were separated over Hypaque/Ficoll, resuspended in RPMI-1640 medium (M.A. Bioproducts, Walkersville, MD) with 10% fetal calf serum, and assayed on the day of separation as described previously (Koenig et al. (1988) Proc. Natl. Acad. Sci USA 85, 8638-8642). Autologous cells were prepared from B lymphocytes obtained from the same patient tested for CTL activity, i.e. to match HLA types for both target and effector cells . Autologous B lymphoblastoid cell lines from these HIV seropositive patients were prepared by transformation wtih fEpstein-Barr Virus (EBV) as described previously (Blumberg et al. (1987) J. Infect. Dis. 155, 877; Koenig et al. (1988) Proc. Natl. Acad. Sci USA 85, 8638-8642). These cell lines were used as targets in an autologous chromium-release assay as described by Koenig, et al. (ibid). In this assay, lysis of labeled target cells results in the release of chromium into the medium. Freshly isolated
autologous PBMC were used as effector cells in the assay. Two subjects had a Nef-specific cytotoxic response that was approximately five-fold higher than that observed for control vaccinia virus infected target cells.
(c) Mapping a Nef-specific CTL epitop . The NEf-specific CTL response of these two donors was further examined by testing a set of peptides individually that spanned the entire Nef protein sequence. Sixteen peptides covering the nef region were synthesized in overlapping linear sequences, 25 residues in length with 13 residue overlaps. The peptides were produced as described in part (d) below. Autologous cells were pulsed with 25 to 50 uM peptide for 12 hours before labeling with Cr-51. Chromium-release assays were performed as described (Koenig et al., op. cit.). One peptide was recognized as a CTL target. This peptide, designated Nef7, corresponds to Nef amino acid residues 73 to 97 according to the Los Alamos National Laboratory HIV sequence database. The N- and C-terminal boundaries of this epitope were fine-mapped by peptide deletions (A summary of peptides used for fine-mapping is shown in Table 1). A 10 residue peptide (10-mer), Nef7B, corresponding to residues 73 to 82 (QVPLRPMTYK) , was capable of serving as the CTL epitope with the same reactivity as Nef7 (25-mer).
Individuals tested exhibiting Nef CTL activity are designated #1 and #2. Peptide NEf7B is contained within a highly conserved region of the Nef protein sequence (at least 90 percent conserved in all HIV-1 isolates sequenced to date). Although these subjects were classified as seropositive by standard screening assays; detection of antibody responses to Nef was negative by radioimmunoassay.
(d) Peptide synthesis. Synthetic peptides were constructed using the stepwise solid phase approach of Merrifield (J. Am. Chem. Soc. (1963) 85, 2149) on an Applied Biosystems Model 430A peptide synthesizer. All synthetic peptides were assembled on an insoluble copolymer "PAM" resin consisting of styrene and divinylbenzene.
The symmetric anhydride derivatives were used as the acylating species for all amino acids except asparagine, glutamine, arginine and histidine. These four amino acids were coupled as the 1-hydroxybenzotriazole esters. The reactive side chains of amino acids were protected during the synthesis. The protecting groups used were 0-benzyl for Asp and Glu; benzyl for Ser and Thr; p-methylbenzyl group for Cys; tosyl for Arg; dinitrophenyl for His; 2-chlorobenzyloxycarbonyl for Lys; 2-bromobenzyloxycarbonyl for Tyr; and formyl for Trp.
Following their syntheses, peptides were cleaved with anhydrous liquid HF in the presence of anisole, dimethlysulfide and ethanedithiol. Once cleaved the peptides were precipitated in ether, and then extracted from the resin with 30% (v/v)glacial acetic acid in water.
The cleaved peptides from the resin were analyzed and subsequently purified to greater than 95% homogeneity, using a Vydac C-4 reverse-phase column, and Beckman "System Gold" HPLC. The correct amino acid content of each peptide was verified by hydrolyzing purified material with constant boiling in 6N HC1 at 150 degrees centigrade for 2 hours . Once hydrolyzed, these samples were then subject to amino acid compositional analysis using the Beckman "System Gold" amino acid analyzer.
(e) CTL assay. Preparation of PBMCs , generation of autologous lymphoblastoid cell lines and cytotoxicity microassays (CTL) were done as described in part (b) above except that the autologous B lymphoblastoid cell line was coated with the Nef7 peptide instead of being infected with the noted viral vector.
(f) Augmenting CTL production in vitro. A protocol which was used for boosting (augmenting) CTLs in vitro is described as follows. Fresh PBMCs from seropositive individuals were separated over Hypaque/Ficoll, resuspended in RPMI-1640 medium containing 10% human serum and 10 ug/ml of Nef7 peptide and incubated for 3 days . After 3 days , cultures were supplemented with recombinant IL-2 at 5 units/ml. At day 5, cultures were restimulated with fresh PMBC pulsed with Nef7 peptide for 3 hours, irradiated with 3000 rads , and washed to remove excess peptide. Cells were restimulated as before on day 14.
Table 1
Overlapping Peptides Positions
QEEEEVGFPVTPQVPLRPMTYKAAV (61-85)
QVPLRPMTYKAAVDLSHFLKEKGGL (73-97)
FPVTPQVPLRPMTYKAAVDLS (68-88)
QVPLRPMTYKAAVDLS (73-88)
QVPLRPMTYK (73-82)
VPLRPMTYK (74-82)
PLRPMTYK (75-82)
LRPMTYK (76-82)
QVPLRPMTY (73-81)
QVPLRPMT (73-80)
QVPLRPMTFK (73-82)
PMTYKAAVDLSHFLKEKGGL (78-97)
AAVDLSHFLKEKGGL (83-97)
SHFLKEKGGL (88-97)
The term "animal" as used herein includes humans and non-humans and is preferably a human. It is to be understood, however, that the scope of the present invention is not to be limited to the specific embodiments described above. The invention may be practiced other than as particularly described, and within the scope of the accompanying claims, numerous modifications may be made of the specific teachings contained herein.
Claims
1. A peptide fragment which includes an epitope which is recognized by CTL induced by one of NEF protein, GAG protein, or ENV protein, or a CTL epitope of such proteins.
2. The peptide fragment of Claim 1 wherein the peptide fragment includes an epitope which is recognized by CTL induced by NEF protein or a CTL epitope thereof.
3. The peptide fragment of Claim 2 wherein the peptide fragment includes a CTL epitope of NEF protein.
4. The peptide fragment of Claim 3 wherein the peptide fragment is comprised of amino acid residues 73 to 97 of NEF protein.
5. The peptide fragment of Claim 3 wherein the peptide fragment is comprised of amino acid residues 73 to 82 of NEF protein, as defined by the single letter amino acid code:
QVPLRPMT(Y or F)K.
6. The peptide fragment of Claim 5 wherein the peptide fragment has the following structural formula:
QVPLRPMTYK.
7. The peptide fragment of Claim 1 wherein the peptide fragment includes an epitope which is recognized by CTL induced by GAG protein or a CTL epitope thereof.
8. The peptide fragment of Claim 7 wherein the peptide fragment includes a CTL epitope of GAG protein.
9. The peptide fragment of Claim 8 wherein the peptide fragment is comprised of amino acid residues 179 to 193 of GAG protein, as defined by the single letter amino acid code:
ATPQDLN(Tor M)MLN(T or I)VGG.
10. The peptide fragment of Claim 9 wherein the peptide fragment has the following structural formula:
ATPQDLNTMLNTVGG
11. The peptide fragment of Claim 1 wherein the peptide fragment includes an epitope which is recognized by CTL induced by ENV protein or a CTL epitope thereof.
12. The peptide fragment of Claim 11 wherein the peptide fragment includes a CTL epitope of ENV protein.
13. The peptide fragment of Claim 12 wherein the peptide fragment is comprised of amino acid residues 566 to 590 of ENV protein, as defined by the single letter amino acid code:
LQLTV GIKQLLAR(I or V)LAVERYL(K or R)DQ.
14. The peptide fragment of Claim 13 wherein the peptide fragment has the following structural formula:
LQLTV GIKQLLARILAVERYLKDQ.
15. The peptide fragment of Claim 12 wherein the peptide fragment is comprised of amino acid residues 54 to 80 of ENV protein, as defined by the single letter amino acid code:
CAS(D or E)A(K or R)(A or S)Y(D,S,K, or E)(T,K, or P)E(V,A,S, or K)HN (V or I)WA(T or K)(H or Q)ACVP(T or S)(D or N)P(N or S).
16. The peptide fragment of Claim 15 wherein the peptide fragment has the following structural formula:
CASDAKAYDTEVHNVWATHACVPTDPN.
17. An assay for determining infection of an animal with HIV virus, comprising: contacting cells from the animal coated with the peptide fragment of Claim 1 with peripheral blood lymphocytes from said animal, said cells being autologous cells or cells compatible with the HLA type of the animal being tested; and determining lysis of said cells to indicate infection of said animal with HIV virus.
18. An assay for determining infection of an animal with HIV virus, comprising: contacting cells coated with the peptide fragment of Claim 4 with peripheral blood lymphocytes from said animal, said cells being autologous cells or cells compatible with the HLA type of the animal being tested; and determining lysis of said cells to indicate infection of said animal with HIV virus.
19. An assay for determining infection of an animal with HIV virus, comprising: contacting cells from the animal coated with the peptide fragment of Claim 5 with peripheral blood lymphocytes from said animal, said cells being autologous cells or cells compatible with the HLA type of the animal being tested; and determining lysis of said cells to indicate infection of said animal with HIV virus.
20. A process for augmenting a CTL response, comprising: contacting peripheral blood lymphocytes from an animal infected with HIV with the peptide fragment of Claim 1.
21. A process for augmenting a CTL response, comprising: contacting peripheral blood lymphocytes from an animal infected with HIV with the peptide fragment of Claim 4.
22. A process for augmenting a CTL response, comprising: contacting peripheral blood lymphocytes from an animal infected with HIV with the peptide fragment of Claim 5.
23. The process of Claim 20 wherein said CTL response is augmented by systemically administering said peptide fragment to an animal infected with HIV.
24. A process for inducing a CTL response, comprising: administering to an animal infected with HIV the peptide fragment of Claim 1.
25. A process for inducing a CTL response, comprising: administering to an animal infected with HIV the peptide fragment of Claim 4.
26. A process for inducing a CTL response, comprising: administering to an animal infected with HIV the peptide fragment of Claim 5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40959689A | 1989-09-19 | 1989-09-19 | |
| US409,596 | 1989-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1991004051A1 true WO1991004051A1 (en) | 1991-04-04 |
Family
ID=23621182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1990/005343 WO1991004051A1 (en) | 1989-09-19 | 1990-09-19 | Peptides including ctl epitopes of hiv proteins and use thereof |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0491844A4 (en) |
| JP (1) | JPH05502442A (en) |
| CA (1) | CA2025634A1 (en) |
| WO (1) | WO1991004051A1 (en) |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992022658A1 (en) * | 1991-06-14 | 1992-12-23 | Institut Pasteur | Recombinant immunogenic actinomycetale |
| WO1993010816A1 (en) * | 1991-12-02 | 1993-06-10 | Board Of Regents, The University Of Texas System | Compositions for eliciting cytotoxic t-lymphocyte responses against viruses |
| US5221610A (en) * | 1988-05-26 | 1993-06-22 | Institut Pasteur | Diagnostic method and composition for early detection of HIV infection |
| WO1993019775A1 (en) * | 1992-03-31 | 1993-10-14 | Medimmune, Inc. | Administration of liposomes containing peptides or proteins including ctl eptitopes of hiv proteins |
| US5603933A (en) * | 1993-08-31 | 1997-02-18 | Board Of Regents, The University Of Texas | CD4 peptides for binding to viral envelope proteins |
| US5705612A (en) * | 1984-10-18 | 1998-01-06 | Institut Pasteur And Centre National De La Recherche Scientifique | NEF peptide encoded by human immunodefiency virus type 1 (HIV-1) |
| EP0939835A1 (en) * | 1996-10-10 | 1999-09-08 | Probe International | Compositions and methods for treating viral infections |
| US5980900A (en) * | 1984-10-18 | 1999-11-09 | Institut Pasteur And Centre National De La Recherche Scientifique | Amino acid DNA sequences related to genomic RNA of human immunodeficiency virus (HIV-1) |
| US5993819A (en) * | 1987-09-08 | 1999-11-30 | Duke University | Synthetic vaccine for protection against human immunodeficiency virus infection |
| US6210873B1 (en) | 1987-08-28 | 2001-04-03 | Board Of Regents, The University Of Texas System | Methods and compositions for the priming of specific cytotoxic T-lymphocyte response |
| WO2001047955A2 (en) * | 1999-12-23 | 2001-07-05 | Medical Research Council | Improvements in or relating to immune responses to hiv |
| US6265539B1 (en) | 1987-08-28 | 2001-07-24 | The University Of Texas System The Board Of Regents | Prophylaxis and therapy of acquired immunodeficiency syndrome |
| US6555112B1 (en) | 1984-11-16 | 2003-04-29 | Institut Pasteur | Peptides derived from the lymphadenopathy-associated virus (LAV) envelope coding region |
| US6894152B1 (en) | 1984-11-16 | 2005-05-17 | Institut Pasteur | Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA |
| US6982086B2 (en) | 2000-02-04 | 2006-01-03 | Duke University | Human immunodeficiency virus immunogenic composition |
| US7045130B1 (en) | 1984-10-18 | 2006-05-16 | Institut Pasteur | Antibodies against antigens of human immunodeficiency virus (HIV-1) |
| US7205102B1 (en) | 1983-09-15 | 2007-04-17 | Institut Pasteur | Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA |
| US7232654B1 (en) | 1983-09-15 | 2007-06-19 | Institut Pasteur | DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1) |
| US7803524B2 (en) | 1994-02-23 | 2010-09-28 | Siemens Healthcare Diagnostics Products Gmbh | Antigenic HIV gp41 chimeric polypeptides comprising the MVP5180/91 epitope SKGKLIS |
| US8507196B1 (en) | 1983-09-15 | 2013-08-13 | Institut Pasteur | Nucleic acid probe of human immunodeficiency virus type 1 (HIV-1), and a method and kit employing this probe for detecting the presence of nucleic acid of HIV-1 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3787002T2 (en) * | 1986-12-30 | 1993-11-25 | Us Health | Synthetic peptides that generate cellular immunity to the AIDS virus and its proteins. |
| WO1989002277A2 (en) * | 1987-08-28 | 1989-03-23 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
-
1990
- 1990-09-18 CA CA002025634A patent/CA2025634A1/en not_active Abandoned
- 1990-09-19 JP JP2513793A patent/JPH05502442A/en active Pending
- 1990-09-19 WO PCT/US1990/005343 patent/WO1991004051A1/en not_active Application Discontinuation
- 1990-09-19 EP EP19900914632 patent/EP0491844A4/en not_active Withdrawn
Non-Patent Citations (4)
| Title |
|---|
| European Journal of Immunology, Volume 19, issued 1989, CULMANN et al., "An antigenic peptide of the HIV-1 NEF Protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules", pages 2383-2386, see entire document. * |
| Journal of Immunology, Volume 145, No. 1, issued 01 July 1990. KOENIG et al., "Mapping The Dine Specificity Of A Cytolytic T Cell Response To HIV-1 nef Protein", pages 129-135. * |
| See also references of EP0491844A4 * |
| The Journal of Experimental Medicine, Volume 170, issued December 1989, TAKAHASHI et al, "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. * |
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8507196B1 (en) | 1983-09-15 | 2013-08-13 | Institut Pasteur | Nucleic acid probe of human immunodeficiency virus type 1 (HIV-1), and a method and kit employing this probe for detecting the presence of nucleic acid of HIV-1 |
| US7232654B1 (en) | 1983-09-15 | 2007-06-19 | Institut Pasteur | DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1) |
| US7205102B1 (en) | 1983-09-15 | 2007-04-17 | Institut Pasteur | Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA |
| US6261564B1 (en) | 1984-10-18 | 2001-07-17 | Institut Pasteur | Peptides of human immunodeficiency virus type 1 (HIV-1) |
| US7119181B1 (en) | 1984-10-18 | 2006-10-10 | Institut Pasteur | DNA sequences and peptides of human immunodeficiency virus (HIV-1) |
| US7045130B1 (en) | 1984-10-18 | 2006-05-16 | Institut Pasteur | Antibodies against antigens of human immunodeficiency virus (HIV-1) |
| US5705612A (en) * | 1984-10-18 | 1998-01-06 | Institut Pasteur And Centre National De La Recherche Scientifique | NEF peptide encoded by human immunodefiency virus type 1 (HIV-1) |
| US5980900A (en) * | 1984-10-18 | 1999-11-09 | Institut Pasteur And Centre National De La Recherche Scientifique | Amino acid DNA sequences related to genomic RNA of human immunodeficiency virus (HIV-1) |
| US6706268B1 (en) | 1984-10-18 | 2004-03-16 | Institut Pasteur | Human deficiency virus type-1 (HIV-1) peptide encoded by the VIF gene |
| US6894152B1 (en) | 1984-11-16 | 2005-05-17 | Institut Pasteur | Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA |
| US6555112B1 (en) | 1984-11-16 | 2003-04-29 | Institut Pasteur | Peptides derived from the lymphadenopathy-associated virus (LAV) envelope coding region |
| US6265539B1 (en) | 1987-08-28 | 2001-07-24 | The University Of Texas System The Board Of Regents | Prophylaxis and therapy of acquired immunodeficiency syndrome |
| US6210873B1 (en) | 1987-08-28 | 2001-04-03 | Board Of Regents, The University Of Texas System | Methods and compositions for the priming of specific cytotoxic T-lymphocyte response |
| US5993819A (en) * | 1987-09-08 | 1999-11-30 | Duke University | Synthetic vaccine for protection against human immunodeficiency virus infection |
| US5221610A (en) * | 1988-05-26 | 1993-06-22 | Institut Pasteur | Diagnostic method and composition for early detection of HIV infection |
| US6235518B1 (en) | 1991-06-14 | 2001-05-22 | Institut Pasteur | Recombinant immunogenic actinomycetale |
| WO1992022658A1 (en) * | 1991-06-14 | 1992-12-23 | Institut Pasteur | Recombinant immunogenic actinomycetale |
| EP0521220A1 (en) * | 1991-06-14 | 1993-01-07 | Institut Pasteur | Recombinant immunogenic actinomycetale |
| WO1993010816A1 (en) * | 1991-12-02 | 1993-06-10 | Board Of Regents, The University Of Texas System | Compositions for eliciting cytotoxic t-lymphocyte responses against viruses |
| WO1993019775A1 (en) * | 1992-03-31 | 1993-10-14 | Medimmune, Inc. | Administration of liposomes containing peptides or proteins including ctl eptitopes of hiv proteins |
| US5603933A (en) * | 1993-08-31 | 1997-02-18 | Board Of Regents, The University Of Texas | CD4 peptides for binding to viral envelope proteins |
| US7803524B2 (en) | 1994-02-23 | 2010-09-28 | Siemens Healthcare Diagnostics Products Gmbh | Antigenic HIV gp41 chimeric polypeptides comprising the MVP5180/91 epitope SKGKLIS |
| EP0939835A1 (en) * | 1996-10-10 | 1999-09-08 | Probe International | Compositions and methods for treating viral infections |
| EP0939835A4 (en) * | 1996-10-10 | 2004-10-27 | Probe Internat | Compositions and methods for treating viral infections |
| WO2001047955A2 (en) * | 1999-12-23 | 2001-07-05 | Medical Research Council | Improvements in or relating to immune responses to hiv |
| US7993651B2 (en) | 1999-12-23 | 2011-08-09 | Medical Research Council | Chimeric human immunodeficiency virus (HIV) immunogens comprising GAG P24-P17 fused to multiple cytotoxic T lymphocyte (CTL) epitopes |
| WO2001047955A3 (en) * | 1999-12-23 | 2002-05-10 | Medical Res Council | Improvements in or relating to immune responses to hiv |
| US6982086B2 (en) | 2000-02-04 | 2006-01-03 | Duke University | Human immunodeficiency virus immunogenic composition |
| US7052699B2 (en) | 2000-02-04 | 2006-05-30 | Duke University | Immunogenic composition |
| US7078039B2 (en) | 2000-02-04 | 2006-07-18 | Duke University | Immunogenic composition |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0491844A4 (en) | 1993-02-17 |
| EP0491844A1 (en) | 1992-07-01 |
| JPH05502442A (en) | 1993-04-28 |
| CA2025634A1 (en) | 1991-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1991004051A1 (en) | Peptides including ctl epitopes of hiv proteins and use thereof | |
| Takahashi et al. | A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160 | |
| McMichael et al. | HLA B37 determines an influenza A virus nucleoprotein epitope recognized by cytotoxic T lymphocytes. | |
| Walker et al. | Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. | |
| Orentas et al. | Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine | |
| Koenig et al. | Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein. | |
| Tomiyama et al. | Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B* 3501 molecules that are associated with the accelerated progression of AIDS. | |
| US6723695B1 (en) | CTL epitopes from EBV | |
| Shirai et al. | Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules. | |
| JP2569185B2 (en) | Synthetic antigen eliciting anti-HIV response | |
| US5840313A (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
| ES2140380T5 (en) | DNA SEQUENCES CODING MODIFIED RETROVIRIC GAG POLYPEPTIDES AND VACCINES CONTAINING OR ADDED THEMSELVES. | |
| EP0605432B1 (en) | Induction of cytolytic t-lymphocytes with cytomegalovirus polypeptides | |
| Van Binnendijk et al. | Human HLA class I-and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein | |
| Dadaglio et al. | Epitope recognition of conserved HIV envelope sequences by human cytotoxic T lymphocytes. | |
| US5976541A (en) | Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope | |
| US5346989A (en) | Peptides for use in induction of T cell activation against HIV-1 | |
| US6207161B1 (en) | Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides | |
| AU662534B2 (en) | Peptides for use in induction of T cell activation against HIV-1 | |
| US20040141995A1 (en) | MHC class I-restricted and MHC class II-restricted EBNA1 peptides | |
| EP0693938B1 (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
| US20050214319A1 (en) | HIV-specific CTL inducing peptides and medicaments for preventing or treating AIDS comprising the peptides | |
| EP0322394A2 (en) | Expression of HIV proteins in E. coli and S. cerevisiae | |
| AU630364B2 (en) | Identification of human t-lymphocyte epitopes in pathogens for vaccine development | |
| US20100310592A1 (en) | A truncated form of the hiv p17 protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1990914632 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1990914632 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1990914632 Country of ref document: EP |